Basic Information
| LncRNA/CircRNA Name | FOXCUT |
| Synonyms | NA |
| Region | GRCh38_6:1605531-1606079 |
| Ensemble | ENSG00000280916 |
| Refseq | NR_125804 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric adenocarcinoma |
| ICD-0-3 | C16 |
| Methods | qPCR |
| Sample | SNU-5, HGC-27, SGC-7901, AGS cells, and normal gastric mucosa cells GES1 |
| Expression Pattern | up-regulated |
| Function Description | Expressions of lncRNA FOXCUT in cancer tissues of GA patients in TCGA database were significantly increased (p<0.001). The survival rate of patients with low expressions of lncRNA FOXCUT was significantly increased (p=0.017, p=0.047). LncRNA FOXCUT is closely related to patients` tumor diameter, lymph node metastasis, TNM staging, and differentiation degree (p<0.05). LncRNA FOXCUT has high clinical value in disease diagnosis. Multivariate Cox regression analysis found that tumor diameter, lymph node metastasis, and lncRNA FOXCUT were independent prognostic factors. Compared with GES1, expressions of lncRNA FOXCUT in GA cells increased significantly (p<0.05), the proliferation and invasion ability of si-RNA group decreased significantly (p<0.05) compared with si-NC group, and the apoptosis rate of si-RNA group was significantly lower than that of si-NC group (p<0.05). |
| Pubmed ID | 31364114 |
| Year | 2019 |
| Title | Verification of expressions of lncRNA FOXCUT in gastric adenocarcinoma patients and its effects on cell biological function based on TCGA database |
External Links
| Links for FOXCUT | GenBank HGNC NONCODE |
| Links for gastric adenocarcinoma | OMIM COSMIC |